内容概要：生物制剂已成为医药行业增长最快的领域之一。随着人口老龄化的加剧以及公众健康意识的 提升，我国创新药市场规模和增长潜力上均表现出强劲的势头。2024年，中国生物制剂市场规模从2019 年的3120亿元增长至5871亿元，预计2025年中国生物制剂市场规模将达到6752亿元，预计未来五年有望 达到11491亿元。首次研发并上市的原研生物制剂亦被称为创新生物制剂。生物制剂代表了现代医学和 生物技术的巅峰成就，是精准医疗的典范。作为全球生物技术研究最为活跃的国家之一，中国在生物制 剂市场的发展中发挥了重要作用。创新仍是核心驱动力，生物制剂行业属于资本密集型，需要大量研发 投资。得益于国家政策利好、研发投入持续增加以及生物技术的显著发展，中国原研生物制剂市场增长 迅速。预计2030年中国生物制剂的研发支出增长至3088亿元，原研生物制剂市场规模为有望突破1万亿 元。 上市企业：舒泰神[300204]、恒瑞医药[600276]、药明生物[02269]、百济神州[06160]、科兴生物 [SVA]、药明康德[603259]、智飞生物[300122]、万泰生物[603392]、长春高新[000661]、凯莱英 [0 ...

经济观察报 记者 张铃 11月23日，歌手张靓颖在社交平台透露自己上月确诊带状疱疹，虽及时治疗仍留下疤痕。 带状疱疹有"最疼皮肤病"之称，民间俗称"蛇缠腰""缠腰龙"。这种病由水痘—带状疱疹病毒引起，多发于50岁以上人群，约三分之一的人一生中至少会得一 次。 张靓颖才41岁，从年龄上看不属于带状疱疹高危人群，但她的职业却是带状疱疹的易发人群。近两年，那英、蔡国庆、蔡依林、欧阳震华等明星都曾公开自 己得带状疱疹的经历。 多数带状疱疹患者可通过抗病毒等方法治愈，但有9%—34%的患者会出现后遗神经痛，这种后遗症比留疤更可怕，因此预防比治疗要更加重要。但是，中 国带状疱疹疫苗接种率却很低，每100位适龄者中仅有不到1人接种过。 北京佑安医院呼吸与感染性疾病科主任医师李侗曾告诉经济观察报记者，医务人员、程序员、艺人等因工作需要经常熬夜、作息不规律的人群，都容易在年 轻时就得带状疱疹。他本人就是40岁时得的带状疱疹，他身边也有不少医生朋友在40岁左右得带状疱疹。 "我真的不能再按照以前的节奏工作了。"张靓颖在发文中写道。 李侗曾说，年轻的明星患者给了年轻人一个提示：长期处于劳累状态会导致免疫力下降，增加得带状疱疹的风险 ...

Investment Rating - The industry investment rating is maintained at "Overweight" [1] Core Views - Vaccine companies are achieving breakthroughs in internationalization and research and development, while the pressure for winter epidemic prevention continues to highlight the need for effective measures [4][9] - The vaccine industry is transitioning from scale expansion to innovation-driven growth, with supply-demand imbalances and homogenized competition causing short-term challenges, but the long-term outlook remains positive due to supportive policies, increasing demand, and technological advancements [9][28] Summary by Sections Recent Developments - Zhifei Biological's subsidiary obtained a U.S. patent for an RSV vaccine, marking a significant step in its international market strategy [3] - Watson Bio's subsidiary received a marketing license for a 13-valent pneumonia vaccine in Egypt, enhancing its international presence [3] - Wuhan Institute of Biological Products achieved important progress in children's vaccine development, with two vaccines approved for clinical use [3] Market Performance - The vaccine sector saw a 1.33% increase last week, underperforming compared to other pharmaceutical sectors [5][6] - Year-to-date, the vaccine sector has experienced a cumulative decline of 5.12% [6] Valuation Metrics - The vaccine sector's PE (ttm) is 95.41X, with a PB (lf) of 1.87X, indicating a slight increase in valuation metrics compared to previous periods [7] Investment Recommendations - The vaccine industry is under pressure, with a focus on innovation and international expansion as key strategies for recovery [8] - Companies with high technical barriers and differentiated pipelines are recommended for investment, particularly those with strong research and development capabilities [9][28]

Core Viewpoint - The article highlights the increasing incidence of shingles among younger individuals, particularly in high-stress professions, and emphasizes the low vaccination rates in China, which poses a significant public health risk [1][2][3]. Group 1: Shingles Incidence and Impact - Shingles, caused by the varicella-zoster virus, is commonly associated with individuals over 50, but recent cases among younger celebrities indicate a rising trend in younger populations, particularly those with high-stress jobs [2][5]. - The pain associated with shingles is severe, with reports indicating that it can reach levels comparable to childbirth, leading to a lack of public awareness regarding its severity and the importance of vaccination [7][9]. Group 2: Vaccination Rates and Challenges - The vaccination rate for shingles in China is alarmingly low, with only 0.79% of adults aged 40 and above vaccinated as of September 2024, compared to higher rates in the U.S. [6]. - The high cost of vaccines, with imported vaccines priced at 3,260 yuan and domestic vaccines around 1,400 yuan, significantly hinders vaccination efforts, especially among retirees with limited income [9][10]. Group 3: Market Dynamics and Pricing Strategies - The vaccine market has seen a price war since 2025, with prices for imported vaccines dropping from 3,260 yuan to 1,652 yuan, and domestic vaccines being offered at half price, which may lead to long-term sustainability issues for vaccine manufacturers [3][11]. - Companies are facing inventory challenges, with a significant drop in vaccine issuance in 2025, indicating a mismatch between supply and demand [11]. Group 4: Public Awareness and Marketing Strategies - There is a notable gap in public awareness regarding shingles and its vaccine, particularly among older adults who are the primary target demographic [13]. - Vaccine companies are utilizing social media and other platforms for marketing, focusing on educating the public about the disease and the availability of vaccines, despite regulatory restrictions on direct advertising [12][14].

张铃 11月23日，歌手张靓颖在社交平台透露自己上月确诊带状疱疹，虽及时治疗仍留下疤痕。 带状疱疹有"最疼皮肤病"之称，民间俗称"蛇缠腰""缠腰龙"。这种病由水痘—带状疱疹病毒引起，多发 于50岁以上人群，约三分之一的人一生中至少会得一次。 张靓颖才41岁，从年龄上看不属于带状疱疹高危人群，但她的职业却是带状疱疹的易发人群。近两年， 那英、蔡国庆、蔡依林、欧阳震华等明星都曾公开自己得带状疱疹的经历。 多数带状疱疹患者可通过抗病毒等方法治愈，但有9%-34%的患者会出现后遗神经痛，因此预防比治疗 要更加重要。但是，中国带状疱疹疫苗接种率却很低，每100位适龄者中仅有不到1人接种过。 北京佑安医院呼吸与感染性疾病科主任医师李侗曾告诉经济观察报记者，医务人员、程序员、艺人等因 工作需要经常熬夜、作息不规律的人群，都容易在年轻时就得带状疱疹。他本人就是40岁时得的带状疱 疹，他身边也有不少医生朋友在40岁左右得带状疱疹。"我真的不能再按照以前的节奏工作了。"张靓颖 在发文中写道。 李侗曾说，年轻的明星患者给了年轻人一个提示：长期处于劳累状态会导致免疫力下降，增加得带状疱 疹的风险。 发文当天，#张靓颖自曝患带状疱疹留 ...

证券代码：300122 证券简称：智飞生物 公告编号：2025-73 特此公告 重庆智飞生物制品股份有限公司董事会 2025 年 11 月 28 日 1 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 重庆智飞生物制品股份有限公司（以下简称"公司"）及全资子公司——安 徽智飞龙科马生物制药有限公司（以下简称"智飞龙科马"）、北京智飞绿竹生 物制药有限公司（以下简称"智飞绿竹"）于近日取得中华人民共和国国家知识 产权局颁发的发明专利证书。具体情况如下： | 发明专利名称 | 专利号 | 专利证书号 | 专利类型 | 专利申请日 | 授权公告日 | 专利权人 | | --- | --- | --- | --- | --- | --- | --- | | CpG 寡聚脱氧核 苷酸、包含其的 | ZL202311196410.3 | 第 8524436 号 | 发明专利 | 2023 年 09 月 | 2025 年 11 月 | 智飞生物 智飞绿竹 | | 佐剂、疫苗及应 | | | | 15 日 | 28 日 | 智飞龙科马 | | 用 | | | | | | | ...

Core Insights - Zhifei Biological's subsidiary, Beijing Zhifei Lvzhu, has successfully obtained invention patent certificates from the U.S. Patent and Trademark Office and the European Patent Office for a combined vaccine targeting respiratory syncytial virus (RSV) infection, showcasing the company's strong independent research and development capabilities and marking a significant recognition of its technological innovation in global core markets [1][3] Group 1: Patent and Innovation - The RSV combined vaccine patent is a significant achievement resulting from deep collaboration between Zhifei Lvzhu and Beijing Jiaotong University, addressing the urgent clinical need for effective preventive measures against RSV, a major pathogen causing lower respiratory infections in infants and the elderly [3] - The patented technology enhances immune response efficiency and broad-spectrum protection through innovative antigen design and delivery strategies, providing safer and more effective preventive measures for high-risk populations [3] - Zhifei Biological has strengthened its intellectual property system, achieving over 60 domestic and international invention patent authorizations, with this patent previously authorized in China and Russia, supporting its globalization strategy and enhancing its core competitiveness in the respiratory disease vaccine sector [3][4] Group 2: International Expansion - The company is accelerating its product internationalization process and enhancing international collaboration, contributing positively to global infectious disease control and exploring new market opportunities [4] - Zhifei's self-developed products have been exported to over 10 countries, with clinical trials or registration efforts underway in nearly 20 countries, including successful market registration of tuberculosis diagnostic reagents in Indonesia and ongoing supply of quadrivalent meningococcal polysaccharide vaccine in several countries [4] - The company is expanding its international layout from preventive to therapeutic areas, with discussions ongoing for therapeutic products like insulin and semaglutide with multiple overseas entities [4][6] Group 3: Future Directions - Zhifei Biological plans to continue its commitment to innovative research and development, strengthen its global intellectual property protection network, and solidify its vaccine research and development technology, aiming to create a competitive product matrix and contribute more Chinese wisdom and solutions to global public health [6]

重庆智飞生物制品股份有限公司 关于全资子公司取得欧洲专利证书的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 证券代码：300122 证券简称：智飞生物 公告编号：2025-72 2025 年 11 月 27 日 1 上述发明专利为智飞绿竹与北京交通大学合作开发一种呼吸道合胞病毒 (RSV)疫苗的过程中申请获得。上述合作开发的 RSV 疫苗目前已获得中国、俄罗 斯、美国的专利授权。公司突破国际市场技术壁垒，首次在欧洲取得专利证书， 为全球化布局奠定基础。该专利证书的取得不会对公司近期生产经营产生重大影 响，但有利于公司进一步完善知识产权保护体系，发挥自主知识产权优势，促进 技术创新，推进公司国际化发展战略，提升公司的核心竞争力。 特此公告 重庆智飞生物制品股份有限公司董事会 重庆智飞生物制品股份有限公司（以下简称"公司"）全资子公司北京智飞绿 竹生物制药有限公司（以下简称"智飞绿竹"）于近日获得欧洲专利局颁发的发明 专利证书。具体情况如下： | 专利名称 | 专利号 | 专利 | 专利申 | 授权公 | 专利权人 | | --- | --- | --- ...

Core Insights - The price war in the vaccine industry is driven by changes in supply and demand dynamics, leading to significant price reductions and financial losses for companies [2][10][15] Group 1: Price Trends - The price of a three-valent flu vaccine has dropped to 5.5 yuan, lower than the price of a cup of milk tea, indicating a drastic reduction in vaccine prices [3][7] - The price of the four-valent flu vaccine has decreased from 128 yuan to 88 yuan, with further reductions expected as competition intensifies [7][8] - HPV vaccines have also seen significant price drops, with the two-valent HPV vaccine priced at 27.5 yuan, down over 90% from previous prices [8] Group 2: Industry Response - The China Vaccine Industry Association issued an initiative to combat "involutionary" competition, urging members to avoid bidding below cost and maintain price stability [4][5] - The association's initiative aims to stabilize price expectations but may not address the underlying issue of overcapacity in the industry [3][10] Group 3: Market Dynamics - The vaccine market is experiencing overcapacity due to an influx of companies entering the sector, leading to intense competition and price wars [10][11] - Demand for vaccines is under pressure, with declining public trust in vaccines and a decrease in birth rates affecting the market for childhood vaccines [11][12] Group 4: Financial Impact - Vaccine companies have reported significant financial losses, with overall revenue for listed vaccine companies dropping by 60% and net profits declining by 113% in the first half of 2025 [12][14] - Major companies like Zhifei Biological and Wantai Biological have reported substantial revenue declines and net losses, reflecting the severe impact of the price war [12][14] Group 5: Future Outlook - Experts suggest that the industry may need to undergo a period of consolidation and restructuring, which could last five to ten years, to address the current challenges [15] - Companies are exploring international markets and differentiation strategies to navigate the competitive landscape, with some reporting significant increases in exports [15]

Core Viewpoint - The article discusses the ongoing price war in China's vaccine industry, driven by changes in supply and demand dynamics, leading to significant price reductions and financial losses for companies [4][15][22]. Group 1: Price War Dynamics - The price of a three-valent flu vaccine has dropped to 5.5 yuan, cheaper than a cup of milk tea, indicating a severe price competition in the vaccine market [5][11]. - The China Vaccine Industry Association has issued an initiative to combat "involution-style" competition, urging members to avoid bidding below cost and threatening penalties for violations [6][8][10]. - The price war has persisted for two years, with the association's initiative being the first formal stance against low-price competition, although it may not resolve the underlying issue of overcapacity [6][10][22]. Group 2: Supply and Demand Changes - The supply side is characterized by homogenization and overcapacity, with many companies entering the vaccine market, leading to intense competition and price wars [16][17]. - Demand is also under pressure, with declining public trust in vaccines and a decrease in vaccination rates, particularly for flu vaccines, which averaged below 4% in China from 2020 to 2023 [17][19]. - The shift in focus from childhood vaccines to adult vaccines due to declining birth rates has intensified competition in the adult vaccine market [17][19]. Group 3: Financial Impact on Companies - The financial repercussions of the price war are evident, with vaccine companies experiencing a 60% drop in revenue and a 113% decline in net profit in the first half of 2025 [19][20]. - Major companies like Zhifei Biological and Wantai Biological have reported significant losses, with Zhifei's revenue down 66.53% and net profit loss of 12.06 billion yuan [20][21]. - Despite some companies showing growth in sales, the overall trend indicates that increased revenue does not equate to increased profit due to drastic price reductions [21][22]. Group 4: Future Outlook and Strategies - Experts suggest that the industry is in a "deep cold moment," requiring a period of consolidation and restructuring that could last five to ten years [23]. - Companies are exploring two main strategies to navigate the competitive landscape: expanding into emerging markets and focusing on differentiated products to meet unmet clinical needs [24].